In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84. ttps://pubmed.ncbi.nlm.nih.gov/35023547
Main Authors: | Mayne, KJ, Herrington, WG |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American College of Physicians
2022
|
Similar Items
-
Bioimpedance in CKD: an untapped resource?
by: Mayne, KJ, et al.
Published: (2022) -
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
by: Sylvia E. Rosas, et al.
Published: (2023-10-01) -
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials
by: John M. Flack, et al.
Published: (2023-12-01) -
Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01) -
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
by: Ng, SYA, et al.
Published: (2020)